

ANNUAL CONGRESS ON MEDICINE

November 05-06, 2018 Bangkok, Thailand

Discovery of EED inhibitor BR554: Preclinical candidate as anti-cancer therapy

Zou Bin

Shanghai Blueray Bio-pharma Co. Ltd., China

W^{D40} repeat (WDR) domain is one of the largest protein families from yeast to human, consisting about 1% total cell protein. WDR proteins generally function as platform of protein-protein interactions and are involved in a wide range of cellular processes. Embryonic Ectoderm Development (EED), a subunit of PRC2 complex, is an important member of WDR family and plays critical role of methylating H3K27. Herein, a novel class of EED inhibitors, represented by BR554, with great drug-like properties, *in vivo* efficacy and favorable toxicology profile.

Biography

Zou Bin is the Co-Founder and CEO of Shanghai Blueray Biopharma, Co., Ltd since 2017. He had more than ten years' experience in global pharma at Novartis Institute for Tropical Diseases, Singapore and discovered antimalarial drug NITD609 to phase II clinical trial. He did a Postdoctoral research with Prof. K. C. Nicolaou in the lab cofounded with A*STAR. He has obtained his PhD from Shanghai Institute of Organic Chemistry under the supervision of Prof. Dawei Ma, after his undergraduate from Nankai University. He was the inventor of number of patents and published 20 papers in high impact journals.

bin.zou@blueraybiopharma.com

Notes: